Ielasi L, Sansone V, Granito A, Benevento F, De Lorenzo S, Tovoli F
Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
Drugs Today (Barc). 2018 Oct;54(10):615-627. doi: 10.1358/dot.2018.54.10.2880176.
Hepatocellular carcinoma (HCC) remains among the neoplastic diseases with the most unfavorable prognosis. Historically, systemic treatments for HCC have been scarce. In particular, sorafenib was the only registered drug for the treatment of unresectable HCC until 2017. Last year, regorafenib was approved by the global regulatory agencies as second-line therapy. Since then, further randomized, controlled trials have been successful in this patient population. This paper deals with the most recent data concerning cabozantinib and ramucirumab, the two drugs that have recently demonstrated efficacy in phase III, randomized, controlled trials in HCC patients who failed previous treatment with sorafenib.
肝细胞癌（HCC）仍然是预后最不理想的肿瘤疾病之一。从历史上看，HCC的全身治疗方法一直很少。特别是，直到2017年，索拉非尼是唯一获批用于治疗不可切除HCC的药物。去年，瑞戈非尼被全球监管机构批准作为二线治疗药物。从那时起，针对该患者群体的进一步随机对照试验取得了成功。本文讨论了关于卡博替尼和雷莫西尤单抗的最新数据，这两种药物最近在先前接受索拉非尼治疗失败的HCC患者的III期随机对照试验中显示出疗效。
